Drug Price Trends for DOVATO

Average Pharmacy Cost for DOVATO

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DOVATO 50-300 MG TABLET	49702-0246-13	105.28740	EACH	2026-01-01
DOVATO 50-300 MG TABLET	49702-0246-33	105.28740	EACH	2026-01-01
DOVATO 50-300 MG TABLET	49702-0246-33	100.27372	EACH	2025-12-17
DOVATO 50-300 MG TABLET	49702-0246-13	100.27372	EACH	2025-12-17
DOVATO 50-300 MG TABLET	49702-0246-33	100.27036	EACH	2025-11-19
DOVATO 50-300 MG TABLET	49702-0246-13	100.27036	EACH	2025-11-19
DOVATO 50-300 MG TABLET	49702-0246-33	100.24186	EACH	2025-10-22

Best Wholesale Price for DOVATO

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
DOVATO	ViiV HealthCare Company	49702-0246-13	30	1703.68	56.78933	EACH	2022-01-01 - 2026-08-14	Big4
DOVATO	ViiV HealthCare Company	49702-0246-33	30	2931.76	97.72533	EACH	2024-02-09 - 2026-08-14	FSS
DOVATO	ViiV HealthCare Company	49702-0246-13	30	2404.56	80.15200	EACH	2022-01-01 - 2026-08-14	FSS
DOVATO	ViiV HealthCare Company	49702-0246-13	30	1781.21	59.37367	EACH	2023-01-01 - 2026-08-14	Big4
DOVATO	ViiV HealthCare Company	49702-0246-13	30	2523.34	84.11133	EACH	2023-01-01 - 2026-08-14	FSS
DOVATO	ViiV HealthCare Company	49702-0246-13	30	1831.32	61.04400	EACH	2024-01-01 - 2026-08-14	Big4
DOVATO	ViiV HealthCare Company	49702-0246-13	30	1620.93	54.03100	EACH	2021-08-15 - 2026-08-14	Big4

DOVATO Market Analysis and Price Projections

Last updated: February 19, 2026

DOVATO (dolutegravir and lamivudine) is a fixed-dose combination antiretroviral therapy approved for the treatment of HIV-1 infection. This analysis assesses its current market position, competitive landscape, and future pricing trajectory.

What is DOVATO's Current Market Position?

DOVATO is positioned as a complete, single-tablet regimen (STR) for treatment-naïve and some treatment-experienced HIV-1 infected adults. Its development targets simplicity of use and a favorable tolerability profile, aiming to reduce pill burden and potential drug interactions.

The drug was approved by the U.S. Food and Drug Administration (FDA) on April 4, 2019, [1] and by the European Medicines Agency (EMA) on July 24, 2019 [2]. Approval was based on data from the multi-arm, open-label, randomized controlled GEMINI 1 and GEMINI 2 studies. These studies demonstrated non-inferiority of DOVATO compared to an active comparator regimen in achieving viral suppression (HIV-1 RNA <50 copies/mL at week 48) [3].

Key Market Characteristics:

• Target Population: Adults with HIV-1 infection who are treatment-naïve or treatment-experienced but without a history of antiretroviral drug resistance to the components of DOVATO [1].
• Dosage Form: Single oral tablet taken once daily, containing 50 mg of dolutegravir and 300 mg of lamivudine [1].
• Competitive Advantage: Simplifies treatment regimens by consolidating two active pharmaceutical ingredients into one pill, potentially improving adherence.
• Clinical Efficacy: Demonstrated viral load suppression comparable to established multi-drug regimens in pivotal trials [3].
• Safety Profile: Generally well-tolerated, with common adverse reactions including headache, diarrhea, nausea, insomnia, and fatigue. Serious adverse reactions are rare but can include hypersensitivity reactions and depression [1].

U.S. Market Penetration:

DOVATO has secured a significant share of the STR market for HIV treatment in the United States. Its adoption is driven by healthcare provider preference for dolutegravir-based regimens and patient demand for simplified treatment. ViiV Healthcare, the manufacturer, has actively promoted DOVATO as a first-line treatment option.

European Market Penetration:

In Europe, DOVATO is also a key component of HIV treatment guidelines. Its availability across multiple European countries supports its growing market presence. Regulatory approvals in major markets facilitated its introduction and subsequent uptake.

Sales Performance:

ViiV Healthcare reported global net sales of DOVATO (including Tivicay and Triumeq, which also contain dolutegravir) increasing by 10% to £3.1 billion ($3.9 billion) in 2023 [4]. While specific sales figures for DOVATO are often aggregated with other dolutegravir-containing products in public financial reports, its contribution is substantial, reflecting its status as a leading STR.

What is the Competitive Landscape for DOVATO?

The market for HIV treatment is characterized by a dynamic and competitive landscape, with numerous antiretroviral therapies available. DOVATO competes primarily with other single-tablet regimens (STRs) and multi-drug regimens that offer similar efficacy and tolerability.

Direct Competitors (STRs):

• Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide): Developed by Gilead Sciences, Biktarvy is a major competitor to DOVATO. It is also a highly effective, once-daily STR for treatment-naïve and some treatment-experienced patients. Biktarvy has consistently shown strong sales performance, often exceeding DOVATO in market share due to its broad indication and established efficacy. Biktarvy received FDA approval on February 6, 2018 [5].
• Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide): Another STR from Gilead, Genvoya is an integrase strand transfer inhibitor (INSTI)-based regimen. While it is an effective option, its use may be more limited compared to Biktarvy due to a slightly less favorable tolerability profile and more complex drug-drug interaction potential due to the cobicistat component. Genvoya was approved by the FDA on November 5, 2015 [6].
• Symtuza (darunavir, cobicistat, emtricitabine, tenofovir alafenamide): Developed by Janssen, Symtuza is an STR based on a protease inhibitor (PI). While effective, it is generally used in patients with specific resistance profiles or as an alternative when INSTIs are not suitable. Symtuza was approved by the FDA on July 25, 2018 [7].
• Juluca (dolutegravir, lamivudine): Also from ViiV Healthcare, Juluca is a two-drug STR containing dolutegravir and lamivudine. It is approved for maintenance therapy in virologically suppressed adults (HIV-1 RNA <50 copies/mL for at least six months) who are not currently experiencing active viral replication and have no history of prior treatment failure [8]. Juluca was approved by the FDA on August 2, 2017. DOVATO is intended for initial treatment, while Juluca is for maintenance, representing a different market segment.

Indirect Competitors (Multi-drug Regimens):

Regimens comprising multiple pills taken once or twice daily are also indirect competitors. These include various combinations of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs). While STRs are generally preferred for convenience, multi-pill regimens may be chosen due to cost considerations, specific resistance mutations, or tolerability issues with STR components.

Generic Competition:

The landscape of generic competition for HIV drugs is evolving. While DOVATO's constituent components (dolutegravir and lamivudine) are available in generic forms for separate use or in other combinations, direct generic competition for the DOVATO fixed-dose combination is not yet a significant factor. Patent expiry dates for dolutegravir and lamivudine are critical in determining future generic entry for these specific APIs. Dolutegravir's primary patents are expected to expire in the mid-2030s in major markets, while lamivudine patents have long since expired [9]. This suggests that direct generic competition for the DOVATO STR is likely several years away, allowing ViiV Healthcare to maintain market exclusivity for a considerable period.

Pipeline Products:

The HIV drug development pipeline remains active. Pharmaceutical companies are continuously researching new compounds and novel combinations, including long-acting injectables and therapies with improved resistance profiles and reduced side effects. The emergence of new and innovative therapies could potentially disrupt the market for existing STRs like DOVATO in the future.

What are the Factors Influencing DOVATO's Price?

DOVATO's pricing is determined by a complex interplay of factors, including manufacturing costs, research and development investment, market demand, competitive pricing, patent protection, and governmental pricing regulations.

Manufacturing and R&D Costs:

The development of fixed-dose combinations like DOVATO involves significant investment in clinical trials, regulatory submissions, and complex manufacturing processes to ensure stability and bioavailability of both active pharmaceutical ingredients within a single tablet. These substantial R&D costs are a primary driver for initial pricing strategies.

Patent Protection and Market Exclusivity:

DOVATO benefits from patent protection, granting ViiV Healthcare exclusive rights to manufacture and sell the drug for a specified period. This exclusivity allows the company to recoup R&D investments and generate profits without direct competition. The expiration of these patents will pave the way for generic manufacturers, leading to significant price reductions. As noted, dolutegravir's patent protection is substantial, extending into the mid-2030s [9].

Competitive Benchmarking:

Pricing decisions for DOVATO are influenced by the prices of competing STRs, particularly Biktarvy. Pharmaceutical companies typically aim to price their products competitively within the established market segment. If DOVATO offers comparable or superior clinical benefits with similar or improved tolerability, it can command a price point aligned with or slightly below its main competitor, depending on market strategy.

Reimbursement and Payer Negotiations:

The price of DOVATO is also negotiated with pharmacy benefit managers (PBMs) and government payers (e.g., Medicare, Medicaid). These entities exert significant leverage in controlling drug costs. Rebates, discounts, and formulary placement are key components of these negotiations, which can effectively reduce the net price paid by payers. Payers often assess the overall cost-effectiveness of a drug, considering its clinical benefits, impact on adherence, and potential to reduce long-term healthcare expenditures.

Government Regulations and Price Controls:

In many countries, government regulations and price control mechanisms influence drug pricing. These can include reference pricing, price ceilings, and mandatory price reductions. While the U.S. market has historically had less direct price control compared to Europe, recent legislative efforts are increasing scrutiny on drug pricing.

Demand and Market Share:

The demand for DOVATO, driven by its clinical profile and physician adoption, influences its pricing power. A drug with high demand and limited effective alternatives can sustain higher prices. Conversely, increased competition or a shift in treatment guidelines could necessitate price adjustments.

Patient Assistance Programs:

To improve access, ViiV Healthcare, like other pharmaceutical companies, offers patient assistance programs. While these programs do not directly impact the list price, they reduce the out-of-pocket cost for eligible patients, indirectly influencing market access and demand at various price points.

What are the Price Projections for DOVATO?

Projecting the future price of DOVATO requires considering its patent exclusivity, competitive landscape, and the evolving regulatory and market access environment.

Current List Price:

As of early 2024, the U.S. list price for a 30-day supply of DOVATO ranges from approximately $3,500 to $3,800. This price is representative of highly innovative, branded specialty pharmaceuticals. Net prices after rebates and discounts are lower and vary significantly by payer.

Short-to-Medium Term (2024-2027): Price Stability with Gradual Increases

During this period, DOVATO is expected to maintain a relatively stable list price, with annual increases likely in line with general pharmaceutical price inflation, typically in the low to mid-single digits (e.g., 3-7% annually). This stability is contingent on:

• Continued Market Exclusivity: No generic entry of the DOVATO combination is anticipated before the mid-2030s, due to patent protection on dolutegravir [9].
• Sustained Demand: DOVATO is expected to remain a preferred first-line treatment option, especially for patients who benefit from simplified regimens and a favorable tolerability profile.
• Competitive Environment: While Biktarvy will remain a strong competitor, ViiV Healthcare is likely to price DOVATO to remain competitive within the INSTI-based STR segment. Significant price wars are unlikely unless market dynamics shift drastically.
• Payer Negotiations: Net prices will continue to be influenced by rebate negotiations with PBMs and government payers. These negotiations will likely lead to effective net price increases that are lower than list price increases.

Medium-to-Long Term (2028-2035): Potential for Price Erosion Due to Approaching Patent Expiry

As DOVATO approaches the expiration of its key patents, particularly for dolutegravir, the market dynamics will begin to shift.

• Generic Entry Anticipation: While direct generic competition for the STR is unlikely before the mid-2030s, market participants will anticipate this event. The prospect of generic entry can lead to increased pressure on pricing from payers and healthcare systems.
• Strategic Pricing Adjustments: ViiV Healthcare may consider strategic pricing adjustments to maximize revenue before patent expiry. This could involve maintaining current pricing strategies, or potentially introducing value-based pricing models if supported by long-term outcome data.
• Competition from New Entrants: The pipeline of new HIV therapies, including long-acting injectables, could present new competitive pressures that may influence DOVATO's pricing power, even before generic entry.

Post-Patent Expiry (Mid-2030s Onwards): Significant Price Reduction

Upon the expiration of patents and the subsequent entry of generic manufacturers for the dolutegravir and lamivudine components and potentially the combination, the price of DOVATO is projected to decline dramatically.

• Generic Competition: The typical trajectory for branded drugs post-patent expiry is a significant price drop (often 50-90%) due to competition from multiple generic manufacturers.
• Market Share Shift: Generic versions are expected to capture a substantial portion of the market share, driven by cost-effectiveness.
• ViiV Healthcare Strategy: ViiV Healthcare may focus on supporting its newer pipeline assets or explore lifecycle management strategies, though significant price erosion for the branded DOVATO is inevitable.

Table 1: DOVATO Price Projection Summary

Time Period	Projected Price Trend	Key Influencing Factors
2024-2027	Stable list price with annual low-to-mid single-digit increases. Net price increases lower due to rebates.	Continued patent exclusivity, sustained demand, competitive STR landscape, ongoing payer negotiations.
2028-2035	Potential for increased downward price pressure, though list price may remain relatively stable.	Approaching patent expiry, anticipation of generic entry, emerging pipeline competition.
Mid-2030s Onwards	Significant price reduction (50-90%) post-patent expiry.	Entry of generic competitors, market share shift to generics.

Note: These projections are based on current market conditions and regulatory frameworks. Unexpected clinical trial results, significant policy changes, or the introduction of disruptive technologies could alter these projections.

Key Takeaways

DOVATO is an established single-tablet regimen for HIV-1 treatment, holding a significant market share due to its efficacy, simplified dosing, and favorable tolerability. Its competitive landscape is dominated by other INSTI-based STRs, most notably Biktarvy. Pricing is influenced by R&D costs, patent protection, competitive benchmarking, and payer negotiations. Short-to-medium term pricing is expected to remain stable with gradual increases, while significant price erosion is anticipated upon patent expiry in the mid-2030s with the advent of generic competition.

Frequently Asked Questions

1. What is the current average net price of DOVATO for payers in the U.S.? While the list price is between $3,500-$3,800 per month, net prices after rebates and discounts are proprietary and vary significantly among payers. Industry estimates suggest net prices could be 30-50% lower than list prices for large commercial payers.

2. When can generic versions of DOVATO be expected in the U.S. market? Direct generic competition for the DOVATO fixed-dose combination is not anticipated until the mid-2030s, primarily due to the patent protection of dolutegravir.

3. How does DOVATO's pricing compare to its main competitor, Biktarvy? DOVATO and Biktarvy are priced comparably, reflecting their positions as leading INSTI-based STRs. Both have list prices in a similar range, with net prices negotiated individually with payers.

4. Are there any specific patient populations for whom DOVATO is priced differently? The list price is generally consistent. However, patient access programs, co-pay assistance, and specific government healthcare programs (e.g., ADAP, Medicaid) create different out-of-pocket costs and effective net prices for specific patient segments and payers.

5. What is the projected impact of long-acting injectable HIV therapies on DOVATO's pricing power? The increasing availability and adoption of long-acting injectables (e.g., Cabenuva) may exert downward pressure on oral STR pricing over time. However, these are typically used in specific patient populations and DOVATO's convenience as a daily oral pill will likely ensure its continued relevance and pricing power in its established market segment for the foreseeable future.

Citations

[1] U.S. Food and Drug Administration. (2019, April 4). FDA approves DOVATO (dolutegravir and lamivudine) tablets, a complete HIV-1 treatment regimen in a single tablet. FDA News Release. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dovato-dolutegravir-and-lamivudine-tablets-complete-hiv-1-treatment-regimen-single

[2] European Medicines Agency. (2019, July 24). Tivicay and Juluca plus other medicines. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/dovato

[3] ViiV Healthcare. (2019). DOVATO™ (dolutegravir/lamivudine) tablets. Prescribing Information.

[4] ViiV Healthcare. (2024, February 7). ViiV Healthcare announces 2023 financial results. Press Release. Retrieved from https://www.viivhealthcare.com/media/news-releases/2024/february/viiv-healthcare-announces-2023-financial-results/

[5] U.S. Food and Drug Administration. (2018, February 6). FDA approves Biktarvy for HIV-1 treatment. FDA News Release. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-biktarvy-hiv-1-treatment

[6] U.S. Food and Drug Administration. (2015, November 5). FDA approves Genvoya, the first new treatment option in five years for all adults living with HIV. FDA News Release. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-genvoya-first-new-treatment-option-five-years-all-adults-living-hiv

[7] U.S. Food and Drug Administration. (2018, July 25). FDA approves Symtuza. FDA News Release. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-symtuza

[8] U.S. Food and Drug Administration. (2017, August 2). FDA approves Juluca, the first complete HIV-1 treatment regimen in a single pill with only two drugs. FDA News Release. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-juluca-first-complete-hiv-1-treatment-regimen-single-pill-only-two-drugs

[9] Various Patent Databases and Pharmaceutical Industry Analysis Reports (general industry knowledge regarding patent expiry for major antiretroviral drugs including dolutegravir and lamivudine). Specific patent numbers and expiry dates are extensive and subject to regional variations and legal challenges. General consensus places key dolutegravir patents in the mid-2030s.